American Russian Cancer Alliance (ARCA)

Radioimmuno Imaging

Dr. Matthew Robinson

VideoVideo

Dr. Matthew Robinson discusses molecular imaging, a main research focus of the American Russian Cancer Alliance (ARCA).
Watch now

A primary effort of the ARCA scientific program has been, and will continue to be, creation of a steady and economically sustainable radionuclide production/delivery system to support the scientific endeavors of Fox Chase Cancer Center and Mtech's Biotechnology Research and Education Program (BREP). To date, production has focused on high-demand, unique, pharmaceutical-grade radioisotopes. This collaborative research is developing radio pharmaceuticals for the detection and treatment of various cancers.

Advanced Imaging for Cancer

Under the support of ARCA, with the collaboration of Advanced Nuclide Technologies, LLC, Dr. Matthew Robinson of Fox Chase Cancer Center, has developed molecular imaging that utilizes a unique antibody found on aggressive breast cancer cells. By attaching a molecule Iodine-124, provided by the Russian Nuclear Industry Network (RNIN), he can specifically tag the antibody on breast cancer cells. This has yielded excellent results in preclinical studies on murine animals, and Dr. Robinson plans to move this research into human breast cancer tumor imaging in upcoming years. Advanced Nuclide Technologies, LLC, designated program coordinator of RNIN, helps to implement the ARCA radioimmunotherapy program by providing technical expertise, logistics support and program development services.

The image to the left shows PET/CT imaging of HER2-positive tumor xenografts with either directly and indirectly labeled radiotracer. C6.5(K-A) diabody was radioiodinated with I124 either (A) directly with Iodogen or (B) indirectly with SHPP. Radiolabeled diabody was administered to scid mice bearing MDA-MB-361 tumor xenografts and animals were imaged 48 hours post-injection.

Standard Imaging

Vs.

Molecular Imaging

  • Gives Positive/Negative answers related to cancer diagnosis
 
  • Give Positive/Negative diagnosis
  • Determins which processes are mutated in a person's cancer
    • Enable physicians to personalize their treatment plan for treating a patients cancer
  • Ability to directly monitor outcomes of targeted therapies

Why Iodine-124?

ARCA
124I- C6.5db results in dramatically reduced kidney accumulation as compared to 64Cu-C6.5db and provided greatly enhanced tumor detection
  • Well-established, clinically validated, methods to attach Iodine to antibodies. Can be used as a surrogate for a therapeutic isotope (131I).
  • 124I has a half-life (4.2 days) that pairs well with the biological half-life of antibody tracers.
  • Radiotracers are cleared frm the body through the kidnets, a radiosensitive organ. When radiometals (e.g. 64Cu) are used, the radioisotope is retained in the kidnes, potentially resulting in renal damage. 124I is not retained in the kidneys.
  • 124I has historically been difficult to obtain in the United States. An alternative, reliable supply of the cyclotron-produced radionuclide is available through ARCA's Russian colleagues.